Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | -0.81% | -12.09% | -49.46% |
Jun. 04 | Inotiv, Inc. Enters into A Fifth Amendment to the Credit Agreement | CI |
Jun. 03 | Inotiv to Pay $35 Million for Canine-Breeding Facility Violations | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.46% | 47.79M | D+ | ||
+46.19% | 55.7B | B- | ||
+39.58% | 39.91B | A | ||
-6.14% | 39.57B | B | ||
-6.65% | 28.16B | C | ||
+12.33% | 26.3B | B- | ||
-21.78% | 18.94B | B | ||
+28.38% | 12.17B | C+ | ||
+24.18% | 12.12B | B+ | ||
-0.35% | 12.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOTV Stock
- Ratings Inotiv, Inc.